BridgeBio Pharma Inc. BBIO on Wednesday announced a recent presentation of interim results from its Phase 3 FORTIFY trial for BBP-418, a treatment for limb-girdle muscular dystrophy type 2I/R9.

The company reported no revenue for the period, and ended 2025 with cash, cash equivalents, and marketable securities of about $318.1 million. ・Capricor is now awaiting the U.S. Food and Drug ...

Data presented at the 2026 Muscular Dystrophy Association meeting could have readthroughs to companies developing therapies ...

A new experimental drug, Nerandomilast, has shown potential in reducing lung inflammation and fibrosis in preclinical models of Idiopathic Inflammatory Myopathy–Associated Interstitial Lung Disease ...

Researchers discovered that R. inulinivorans plays an important role in muscle strength and could act as a probiotic candidate for nutraceutical interventions targeting age-related muscle-wasting ...

BridgeBio Pharma has taken another step toward the potential approval of its muscle weakness drug candidate BBP-418, ...

Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder, affecting 12%–13% of adolescents in the United States, according to some studies. The pattern of inattention, ...

The Rev. Steve Gaines, former president of the Southern Baptist Convention and former pastor of Gardendale’s First Baptist ...

So many options. So much noise. Here's what to know about GLP-1s now.

Brianna "Chickenfry" LaPaglia, in a March 10 TikTok video, got candid about the growing use of GLP-1 weight loss medication.

A Florida couple’s love story, which began with sunset walks and kayaking, has taken an unexpected and heartbreaking turn.

More ticks in the U.S. Northeast now carry multiple diseases, raising risks as Lyme and babesiosis co-infections climb.